You are here:

levetiracetam (Keppra)

Advice

Following an abbreviated submission:

levetiracetam 100mg/ml oral solution (Keppra®) is accepted  for restricted use within NHS Scotland.

Indication under review: adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children and infants from 1 month of age to 4 years with epilepsy.

SMC restriction: to initiation and management under the supervision of a paediatric neurologist.
The Scottish Medicines Consortium has previously accepted this product for use within NHS Scotland as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 years of age with epilepsy.

Addition of levetiracetam to existing anticonvulsant therapy has shown a greater reduction in partial seizure frequency than addition of placebo.

Levetiracetam is listed in the British National Formulary for Children 2010-2011 for adjunctive treatment for partial seizures with or without secondary generalisation from 1 month old.

Smaller syringe sizes of 1 and 3 ml have been made available to accommodate the smaller volumes for younger children.

Drug Details

Drug Name: levetiracetam (Keppra)
SMC Drug ID: 661/10
Manufacturer: UCB Pharma Ltd
Indication: Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children and infants from 1 month of age to 4 years with epilepsy
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 17 January 2011

Back